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PSYCHOTIC SYMPTOMS DURING STIMULANT TREATMENT FOR 
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
SINTOMAS PSICÓTICOS DURANTE O TRATAMENTO COM PSICOESTIMULANTES PARA A PERTURBAÇÃO 
DE HIPERATIVIDADE COM DÉFICE DE ATENÇÃO
ABSTRACT
 
Introduction: Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder. Pharmacological treatment, either 
alone or in combination with psychosocial interventions, is important in the therapeutic strategy. Psychostimulants remain the most effective 
medication and are generally well tolerated. However, one of its rare but significant side effects is development of psychotic symptoms. 
Objectives: To perform a literature review about the risk of psychotic symptoms during ADHD treatment with stimulants and discuss possible 
pharmacological treatment implications.
Methods: A literature search was conducted on PubMed database using the terms “ADHD”, “central nervous system stimulants”, and 
“psychosis”. The search was supplemented with data retrieved from published guidelines.
Results and discussion: ADHD diagnosis has been increasing, as well the use of stimulants for its treatment. However, using these drugs 
is not without controversy. ADHD pharmacological treatment is rarely associated with psychotic symptoms. Reported symptoms include 
hallucinations and paranoid delusions, and occasionally also euphoria, grandiosity, and other mania and hypomania features. These 
symptoms are generally short-lived and self-limited within days after stimulant discontinuation. One study comparing amphetamines and 
methylphenidate suggested that the former was more likely to cause psychosis compared with the latter. Additionally, study authors agreed 
that stimulant-induced psychosis seems to be associated to susceptibility factors.
Conclusion: Psychostimulants are highly beneficial for ADHD patients. However, small studies and case reports suggest an association with 
new-onset psychotic symptoms. Physicians should be aware that psychotic symptoms may arise during stimulant ADHD treatment. Further 
investigation is required to identify patients who are most at risk of experiencing such adverse events. 
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RESUMO
Introdução: A perturbação de hiperatividade com défice de atenção (PHDA) é uma perturbação do neurodesenvolvimento comum. 
O tratamento farmacológico, isoladamente ou associado a intervenções psicossociais, constitui um elemento importante na estratégia 
terapêutica global. Os psicoestimulantes continuam a ser os fármacos mais efetivos sendo geralmente bem tolerados. Contudo, o aparecimento 
de sintomatologia psicótica é um efeito adverso raro, mas significativo, que lhes está associado.
Objetivos: Efetuar uma revisão de literatura sobre o risco de desenvolvimento de sintomas psicóticos associados à utilização de estimulantes 
no tratamento da PHDA e discutir possíveis implicações terapêuticas.
Métodos: Foi efetuada uma pesquisa bibliográfica na base de dados PubMed utilizando os termos “PHDA”, “estimulantes do sistema nervoso 
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central” e “psicose”, tendo sido posteriormente complementada com informação recolhida de recomendações formais publicadas sobre o 
tema.
Resultados e Discussão: O diagnóstico de PHDA tem vindo a aumentar, assim como a prescrição de estimulantes para o seu tratamento. 
No entanto, a utilização destes fármacos não é desprovida de controvérsia, tendo sido pontualmente observados sintomas psicóticos 
associados à sua utilização. Os sintomas descritos incluem alucinações, delírios paranoides e, ocasionalmente, euforia, grandiosidade ou 
outras características de mania ou hipomania. Habitualmente, estes sintomas são autolimitados e de curta duração, cessando alguns dias 
após a suspensão do estimulante. Um estudo que comparou a utilização de anfetaminas e metilfenidato sugere que as primeiras são mais 
propensas a causar este tipo de sintomas. Os autores do estudo consideraram ainda que a psicose induzida por estimulantes parece estar 
associada a fatores de suscetibilidade.
Conclusão: Os psicoestimulantes são altamente benéficos para indivíduos com PHDA. Contudo, pequenos estudos e relatos de casos 
sugerem uma associação a sintomas psicóticos de novo. Os médicos devem estar cientes de que podem surgir sintomas psicóticos associados 
à utilização de estimulantes no tratamento da PHDA. São necessários mais estudos que permitam identificar quais os doentes com maior risco 
de desenvolver este tipo de reação adversa.
Palavras-chave: PHDA; anfetamina; metilfenidato; psicoestimulantes; sintomas psicóticos
INTRODUCTION
Attention-deficit hyperactivity disorder (ADHD) is a common 
neurodevelopmental disorder that begins in childhood and 
frequently persists into adolescence and adulthood.1-5 The diagnosis 
is based on clinical evaluation of whether the child presents excessive 
inattention, hyperactivity, and/or impulsivity, associated with high 
levels of functional impairment and reduced quality of life.6,7 The 
estimated prevalence in children and adolescents ranges between 
3% and 8%, with boys more likely to be diagnosed than girls.4-8 ADHD 
etiology is not completely understood, but seems to be multifactorial 
involving genetic, environmental, and social factors.4-5 Current ADHD 
treatments include a range of social, psychological, behavioral, 
and pharmacological interventions.5,9 According to guidelines, 
psychosocial interventions are initially recommended for younger 
children and for cases with mild-to-moderate symptoms. For more 
severe ADHD symptoms, medication, either alone or in combination 
with psychosocial intervention, is an important element in the 
therapeutic strategy.1-3,5,9,10 Psychostimulants have remained the most 
effective medication for ADHD over the last decades, particularly 
methylphenidate and amphetamines, which are generally well 
tolerated.1,2,4,5,9,11 Efficacy and safety of these medications is supported 
by an extensive literature of controlled studies. Nevertheless, like 
other psychotropic medications, psychostimulants have a wide 
range of potential adverse effects. An uncommon but significant 
undesirable side effect is development of psychotic symptoms.1,6,11-17 
Because so many people, especially children and adolescents, are 
prescribed methylphenidate and amphetamines, it is relevant to 
better understand the risk of psychosis associated with these drugs, 
as it can be a traumatic event for patients and families. 
OBJECTIVES 
The aim of this study was to perform a literature review investigating 
the risk for psychotic symptoms associated with ADHD treatment 
with stimulants and discuss possible implications on pharmacological 
treatment.
METHODS
A non-systematic literature review was performed in PubMed 
database using the terms “ADHD”, “central nervous system 
stimulants”, and “psychosis” without setting a specific time period. 
The electronic search was performed during April 2019 and yielded 
106 results. Titles and abstracts of retrieved articles were screened 
and a manual selection of papers was subsequently performed, based 
on their relevance for the subject in matter. No restriction criteria 
were established regarding study design. Eligibility criteria for full-
text articles of records deemed potentially relevant included studies 
with patients diagnosed with ADHD according to the International 
Classification of Diseases (ICD) or the Diagnostic Statistical Manual 
(DSM) diagnostic criteria and reports of patients with psychotic 
symptoms during methylphenidate or amphetamine treatment or 
up to 60 days after withdrawal. Exclusion criteria comprised the 
use of other medications for ADHD management (e.g. atomoxetine) 
and articles reporting assessment of substance-abuse psychosis. 
Further bibliographic references were retrieved from review articles 
and guidelines. Only English language reports were included. 
Finally, 33 eligible studies were identified, including observational 
studies (comparative and non-comparative cohort studies, patient-
control studies, one naturalistic observational study, cross-sectional 
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studies, and a Phase IV open-label study in Europe), patient reports/
series, comprehensive and systematic reviews of clinical data from 
randomized controlled trials, and meta-analyses. 
RESULTS AND DISCUSSION
The number of children and adults diagnosed with ADHD is steadily 
increasing in several parts of the world, including North America 
and Europe.18-20 Consequently, stimulant prescription has also 
dramatically increased.11,18,19 Methylphenidate and amphetamines 
have been used for decades with no specified preference of one 
over the other.11,21,22 Additionally, current guidelines are inconsistent 
in treatment recommendations. Some rank methylphenidate 
over amphetamine for children, while others recommend 
psychostimulants as first-line treatment without distinguishing 
between drugs.2,5,23 Amphetamine is available for use as 
dexamphetamine, mixed-amphetamine salts (levoamphetamine plus 
dextroamphetamine), or lisdexamphetamine, a dexamphetamine 
prodrug and the only formulation available in Portugal.4,7 Generic 
and branded methylphenidate are also available, including long-
acting and immediate-, extended-, and slow-release formulations. 
Methylphenidate is the most frequently prescribed drug globally, 
with recent data showing that amphetamine is more commonly 
used in the United States and Canada.4,11,16,21 Both stimulant types are 
thought to enhance dopamine and noradrenaline efflux in the central 
nervous system.4,18,21 However, while methylphenidate acts on their 
reuptake inhibition, amphetamine brings about reuptake blockade 
and presynaptic release, resulting in higher dopamine availability 
within the synaptic cleft.4,11,18
ADHD-prescribed stimulants are considered equivalent regarding 
standard efficacy endpoints, with some patients better responding to 
and tolerating one drug over the other.4,7,10,11,21,25 Typical side effects 
include decreased appetite, weight reduction, initial insomnia, 
somnolence, headache, and rebound irritability, which are generally 
acceptable for being mild and/or temporary.4,7,10,26 Yet, safety of 
these medications remains controversial.21 Hallucinations and other 
psychotic symptoms have been reported as additional uncommon 
significant adverse effects.3,4,11,16,18,25,27,28 
Some side effects may be too uncommon to be detected in 
randomized controlled trials (RCTs), particularly when rare, delayed, 
or observed in specific patient subgroups. For this reason, cohort 
studies, patient-control studies, and even patient reports/series 
included in this review may be of value. Systematic reviews and 
meta-analyses were also included in article selection, some of which 
belonging to The Cochrane Library, a collection of systematic reviews 
that follows a scientifically rigorous protocol to generate robust 
evidence.
Stimulant-induced psychosis
Stimulant-induced psychosis has been described since the 1950s 
in individuals abusing amphetamine and methamphetamine.19 
Psychosis literature review showed that few data exists regarding this 
phenomenon in ADHD. Most published data concerns clinical case 
reports, case series, and small clinical trials. In these studies, the term 
“psychosis” is defined at symptom level and does not imply a full-
blown psychotic disorder.10,26 The most reported psychosis symptoms 
are hallucinations and paranoid delusions, and occasionally also 
euphoria, grandiosity, and other mania and hypomania symptoms are 
described.6,10,15,25-27 All revised studies showed that stimulant-induced 
psychosis is generally short-lived, can occur at therapeutic levels, and 
resolves within days after stimulant discontinuation.11,15,16,20,26,27 In 
the vast majority of cases, there was no personal or family history 
of psychiatric disorder. To the best of our knowledge, affected 
patients have not used recreational drugs, although some assumed 
having taken higher-than-prescribed doses.20 No other risk factors 
were identified potentially accounting for reported psychosis or 
mania-related events.6,18,20,26,28-30 Study authors agree that stimulant-
induced psychosis appears to be related to susceptibility factors.29,30 
Several common genetic biomarkers have been identified between 
amphetamine-induced psychosis and schizophrenia, which may 
justify why some patients are more vulnerable to amphetamine-
induced psychosis and probably other stimulants.30,31 In healthy 
individuals, some authors consider that a high stimulant dose 
over a short period of time plays an important role in psychosis 
development. However, that does not explain why some individuals 
develop psychotic symptoms at a certain stimulant dose and others 
do not. In this context, it was hypothesized that the relationship 
between stimulant-induced psychosis and primary psychosis could 
be perceived within the framework of a stress vulnerability paradigm. 
Individuals with lower stress vulnerability require higher stimulant 
doses to precipitate acute psychosis than highly stress vulnerable 
individuals. The least susceptible individuals are those who took 
stimulants but never experienced psychosis. Conversely, the most 
vulnerable individuals are schizophrenic patients who become 
psychotic without using any stimulants at all. The stress vulnerability 
paradigm assumes that the more life stressors an individual has, the 
lower the psychosis threshold.29-31
A few years ago, the Food and Drug Administration (FDA) sought to 
evaluate the frequency of psychotic- or manic-like stimulant reactions 
in ADHD patients.24,25 Based on results from a small preapproval trial, 
as well as on post-marketing spontaneous reports, FDA required 
ADHD drug manufacturers to include in US package inserts warnings 
about psychiatric side effects in patients with no prior history of 
psychosis.6,11,20,21,24-26
Comparative risk
Until now, very few data has been reported on the comparative 
risk of psychosis during treatment with methylphenidate and 
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amphetamines.16 In a recent cohort study using insurance claim 
databases, the authors followed 221.486 teens and young adults 
with ADHD aged 13 to 25 years who were prescribed stimulants 
for the first time. Half of the study cohort received amphetamines 
and the other half methylphenidate. Researchers subsequently 
investigated whether patients had a psychosis diagnosis within four 
to five months severe enough to warrant antipsychotic medicine. 
New-onset psychotic symptoms occurred in 343 (approximately 
0.15%) teens and young adults. The risk of this rare but serious side 
effect was twice as high among patients taking amphetamines than 
among those taking methylphenidate (0.21% vs. 0.1%).11,16 Study 
authors considered that the different biological mechanisms of 
methylphenidate and amphetamine activity on neurotransmitters 
could explain findings.11 This data is consistent with a meta-analysis 
of randomized trials suggesting a more favorable safety profile for 
methylphenidate than for amphetamine in young patients.32
Risk of developing schizophrenia
Some evidence suggests that vulnerability to psychostimulant-
induced psychosis and schizophrenia may be physiologically and 
genetically related.13,33 However, there is no agreement on the 
predictive value of psychotic symptoms associated with the use of 
psychostimulants in children.33 
Several studies indicate that patients with schizophrenia, 
schizotypal personality traits, and family history of such psychiatric 
disorders are more prone to psychotic episodes associated with the 
use of stimulants.13,27,30 The “dopamine hypothesis of schizophrenia” 
attributes psychotic symptoms to hyperactive dopaminergic signal 
transduction. At the same time, psychostimulants increase dopamine 
levels in some cerebral regions. Combination of these two factors 
causes dopamine overflow in the central nervous system, making the 
patient more likely to suffer from stimulant-induced psychosis.13,30,33
In contrast to schizophrenic psychosis, which follows a chronic 
course, stimulant-induced acute psychosis seems to have a brief 
duration and resolve with abstinence.13,16,25-27 Still, symptoms persist 
for more than one month in a minority of patients, suggesting 
prodromal schizophrenia symptoms that were exacerbated by 
psychostimulant use or an underlying schizophrenia vulnerability 
triggered by psychostimulant use.13,27,29,30 
To further complicate the picture, FDA reported that 8% of patients 
with psychosis secondary to psychostimulants were diagnosed with 
schizophrenia or bipolar disorders after some years.13,27,33 Some 
authors argued that ADHD-like symptoms may be a premorbid 
psychotic disorder state, particularly among patients with early-
onset psychosis.3,19,33 Interestingly, it has been reported that 
childhood history of ADHD is common in patients suffering from 
chronic psychotic disorders.3,19,33 Several possible explanations can 
be put forward to account for this association, including genetic 
susceptibility, neurobiological pathophysiology, family history, and 
social environmental factors.3,30,31 A population-based study in a 
large sample of 73.049 ADHD-newly diagnosed patients and 73.049 
controls from Taiwan’s National Health Insurance database found 
that ADHD alone is a risk factor for psychotic disorders.3 This study 
also suggested that patients with ADHD taking psychostimulants had 
a significantly increased risk of developing psychotic symptoms, but 
not schizophrenia.3,30,31
CONCLUSION
Psychostimulants are highly beneficial for ADHD patients and 
a valuable part of their treatment. However, as expected from 
pharmacological profile, these drugs are associated with new-onset 
psychotic symptoms, even at therapeutic doses.18,27 Episodes tend to 
occur early in the course of therapy, resolve with drug discontinuation, 
and present no immediate danger, but may be particularly traumatic 
and undesirable both for patients and parents.18,20,27 In most reported 
stimulant-induced psychosis cases, no preexisting psychiatric 
comorbidities or substance abuse history were identified.18 Thus, 
physicians should be aware that psychotic symptoms may arise 
during ADHD stimulant treatment and caregivers should be educated 
about this side effect.20,27
One study comparing two commonly prescribed stimulants − 
amphetamines and methylphenidate − suggested that amphetamines 
are more likely to cause psychosis than methylphenidate.11 However, 
one non-randomized/controlled single study based on a national 
insurance claim database is not enough to decide on the best course 
of action for these patients.
Further investigation is necessary to identify patients who are 
most at risk of psychotic episodes. Until risk factors are clarified, 
caution should be exercised when treating ADHD in patients with 
a history of psychotic episodes or with family history of psychotic 
disorders.6,11,26,28 Since there is no strong evidence that stimulant-
induced psychosis is associated with future schizophrenic or bipolar 
disorders, psychostimulants should remain first-line pharmacological 
treatments for ADHD, maintaining patients on close supervision.26,33 
The potential benefits of stimulant therapy on children’s behavior, 
family life, and school functioning should be weighed against possible 
risks.10
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